$SENORES

$SENORES Fundamental: Revenue +53.4% YoY | PAT +77.3% YoY | P/E 38.1x vs sector 43.1x (11% discount) | Upside 27.2% | Operating Margin 34.2% | ROCE 14.4% | Rank #2/51 peers | Rating 8.88 Technical: Above all key EMAs sustained bullish structure | Rallied from ₹900, now approaching swing high at ₹1,180 | RSI 63 — healthy momentum | ADX ~35 — strong trend | 52W Index 72.7 Moat: Niche US-focused generic pharma with a high-margin formulations portfolio — 34%+ operating margins signal deep product differentiation and pricing power uncommon at this market cap. View: Top-ranked in segment, deeply profitable, trading at a discount to peers — strong earnings trajectory with institutional accumulation makes this a quality small-cap compounder at a reasonable entry.